KRAS and adenoma: RNF43 mutations have been observed in BRAF-mutant sessile or traditional serrated adenomas, but not in their KRAS-mutant counterparts [99], suggesting that the alternate modalities of MEK–ERK pathway activation may determine the method by which the Wnt pathway is activated.